These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 9648598

  • 1. Secondary response of ovarian tumors to topotecan treatment.
    Dunton CJ, Neufeld J, Carlson JA.
    Gynecol Oncol; 1998 Jun; 69(3):258-9. PubMed ID: 9648598
    [Abstract] [Full Text] [Related]

  • 2. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K.
    Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
    [Abstract] [Full Text] [Related]

  • 3. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [Abstract] [Full Text] [Related]

  • 4. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, Hoppel CL.
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
    Spannuth WA, Leath CA, Huh WK, Barnes MN, Davidson SA, Kilgore LC, Partridge EE, Austin JM, Alvarez RD.
    Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B, Hansen HH, Høgdall C, Engelholm SA.
    Cancer; 2002 Oct 15; 95(8):1656-62. PubMed ID: 12365013
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S.
    J Clin Oncol; 2004 Jul 01; 22(13):2635-42. PubMed ID: 15226331
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.